Tirzepatide Research Dosage: Published Protocol Reference
Tirzepatide dosage references vary by route and study context. The database lists Subcutaneous injection (diabetes): 2.5-15 mg, Once weekly and Subcutaneous injection (weight): 2.5-15 mg, Once weekly. These are research-context references, not a universal protocol.
Direct Answer
Tirzepatide is now the default evidence-backed winner for weight loss among approved incretin drugs: SURMOUNT-5 showed greater weight reduction than semaglutide, and Zepbound also has an FDA indication for moderate-to-severe OSA in adults with obesity. Semaglutide still leads on mature cardiovascular outcomes evidence, but tirzepatide leads on weight-loss magnitude.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Obesity, type 2 diabetes, obstructive sleep apnea with obesity, metabolic syndrome research
Research Dosage References
- <strong>Subcutaneous injection (diabetes)</strong> - 2.5-15 mg - Once weekly - Start at 2.5mg for 4 weeks, then increase. Target 5mg, 10mg, or 15mg (Mounjaro).
- <strong>Subcutaneous injection (weight)</strong> - 2.5-15 mg - Once weekly - Gradual escalation over 20 weeks to maximum tolerated dose (Zepbound).
Half-Life
~5 days.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Tirzepatide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Boxed warning: thyroid C-cell tumors in rodents
- Contraindicated with MTC history
- Pancreatitis risk
- Hypoglycemia with insulin or sulfonylureas
- Not studied in severe GI disease
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Weight Loss (Level A), Blood Sugar Control (Level A), Obstructive Sleep Apnea (Level A), and GI Side Effects (Level A) |
| Primary citation count | 4 |
| Last reviewed | 2026-06-01 |
Related Guides
How to Cite This Page
ExaminePeptides. "Tirzepatide Research Dosage: Published Protocol Reference." Last reviewed 2026-06-01. https://examinepeptides.com/answers/tirzepatide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.